Perrigo Company plc said it settled the Hatch-Waxman litigation relating to Onexton Gel brought by Valeant Pharmaceuticals North America LLC and Dow Pharmaceutical Sciences, Inc.
Details of the settlement are confidential.
“Onexton Gel (clindamycin phosphate 1.2% and benzoyl peroxide 3.75%) is a prescription medicine indicated for the topical treatment of acne vulgaris in patients 12 years of age and older,” said Perrigo.
“Branded market sales for the 12 months ending August 2017 were approximately $120 million.”
Perrigo Executive Vice President and President, Rx Pharmaceuticals John Wesolowski said: “This settlement is another example of long-term investment in our extended topical strategy.
“The Rx team continues to invest in bringing important products to market that provide savings to patients and healthcare systems.”